MEDULLARY THYROID CANCER THAT STAINS NEGATIVE FOR CA 19-9 HAS DECREASED METASTATIC POTENTIAL
Presently, no clinical tools are available to diagnose the metastatic potential of medullary thyroid cancer (MTC) at disease presentation. Surveillance with calcitonin (Ct) and carcinoembryonic antigen (CEA) is currently recommended for the observation and diagnosis of metastatic disease after initi...
Gespeichert in:
| Veröffentlicht in: | Endocrine practice 2015-06, Vol.21 (6), p.590-594 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 594 |
|---|---|
| container_issue | 6 |
| container_start_page | 590 |
| container_title | Endocrine practice |
| container_volume | 21 |
| creator | Milman, Sofiya Arnold, Jeffrey L Price, Melissa Negassa, Abdissa Surks, Martin I Fleischer, Norman Whitney, Kathleen D |
| description | Presently, no clinical tools are available to diagnose the metastatic potential of medullary thyroid cancer (MTC) at disease presentation. Surveillance with calcitonin (Ct) and carcinoembryonic antigen (CEA) is currently recommended for the observation and diagnosis of metastatic disease after initial treatment of MTC. Recently, carbohydrate antigen (CA)19-9 staining has been associated with aggressive forms of MTC and metastatic spread. This pilot study explored whether positive CA19-9 staining of MTC tissue is associated with its metastatic potential.
Sixteen cases of MTC were identified, and tissue specimens were immunostained for CA 19-9 and other MTC tumor markers. Clinical information about patients' MTC was collected through a retrospective chart review.
Overall, 63% of the specimens stained positive for CA19-9. The median size of positively staining specimens was 2.6 cm (interquartile range [IQR] 1.2-3.2) compared to 0.7 cm (0.5-1.2) in negatively staining MTC specimens (P = .04). All specimens from patients diagnosed with stage IV MTC stained positive for CA19-9, compared to only 40% of cases that were classified as stages I to III (P = .03). Furthermore, 100% of the primary specimens that were documented to have metastatic spread stained positive for CA19-9. The sensitivity for ruling out stage IV MTC based on negative staining for CA 19-9 was 100%.
Based on these results, we conclude that negative staining of MTC for CA19-9 may be associated with its decreased metastatic potential. |
| doi_str_mv | 10.4158/EP14357.OR |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4573545</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3785957011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-d0f15d1be3891aaba8454ea9cae3fd34d83022a408e625763f05028f9f54ed463</originalsourceid><addsrcrecordid>eNpdkV9LwzAUxYMobv558QNIwBcRqkmTtM2LELroCnUdXSYKQsjaVDe2VdtN8NsbcQ716d7L-XE4lwPACUaXFLPoSg4xJSy8zPId0MWcUM-niOy6nRHkRRw_dMBB284Q8hHH0T7o-CzEQeDzLni6k71xmor8Ear-Y54lPRiLQSxzdwoFR0okgxEcyFuhknsJb7Lc6RBzj8O-GMGejHMpRrIH76QSjlZJDIeZkgOViPQI7FVm3trjzTwE4xup4r6XZrdJLFKvoChYeSWqMCvxxBKX1ZiJiSij1vDCWFKVhJYRQb5vKIps4JIHpEIM-VHFK4eVNCCH4Prb93U9WdiysMtVY-b6tZkuTPOhazPVf5Xl9EU_1--aspAwypzB-cagqd_Wtl3pxbQt7HxulrZetxoHnIQYMUYdevYPndXrZune0zhEAQ45i5CjLr6poqnbtrHVNgxG-qs0vSlNZ7mDT3_H36I_LZFPdnCJNg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1706179580</pqid></control><display><type>article</type><title>MEDULLARY THYROID CANCER THAT STAINS NEGATIVE FOR CA 19-9 HAS DECREASED METASTATIC POTENTIAL</title><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Milman, Sofiya ; Arnold, Jeffrey L ; Price, Melissa ; Negassa, Abdissa ; Surks, Martin I ; Fleischer, Norman ; Whitney, Kathleen D</creator><creatorcontrib>Milman, Sofiya ; Arnold, Jeffrey L ; Price, Melissa ; Negassa, Abdissa ; Surks, Martin I ; Fleischer, Norman ; Whitney, Kathleen D</creatorcontrib><description>Presently, no clinical tools are available to diagnose the metastatic potential of medullary thyroid cancer (MTC) at disease presentation. Surveillance with calcitonin (Ct) and carcinoembryonic antigen (CEA) is currently recommended for the observation and diagnosis of metastatic disease after initial treatment of MTC. Recently, carbohydrate antigen (CA)19-9 staining has been associated with aggressive forms of MTC and metastatic spread. This pilot study explored whether positive CA19-9 staining of MTC tissue is associated with its metastatic potential.
Sixteen cases of MTC were identified, and tissue specimens were immunostained for CA 19-9 and other MTC tumor markers. Clinical information about patients' MTC was collected through a retrospective chart review.
Overall, 63% of the specimens stained positive for CA19-9. The median size of positively staining specimens was 2.6 cm (interquartile range [IQR] 1.2-3.2) compared to 0.7 cm (0.5-1.2) in negatively staining MTC specimens (P = .04). All specimens from patients diagnosed with stage IV MTC stained positive for CA19-9, compared to only 40% of cases that were classified as stages I to III (P = .03). Furthermore, 100% of the primary specimens that were documented to have metastatic spread stained positive for CA19-9. The sensitivity for ruling out stage IV MTC based on negative staining for CA 19-9 was 100%.
Based on these results, we conclude that negative staining of MTC for CA19-9 may be associated with its decreased metastatic potential.</description><identifier>ISSN: 1530-891X</identifier><identifier>EISSN: 1934-2403</identifier><identifier>DOI: 10.4158/EP14357.OR</identifier><identifier>PMID: 25716629</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Adolescent ; Adult ; Aged ; CA-19-9 Antigen - analysis ; Carcinoma, Neuroendocrine - chemistry ; Carcinoma, Neuroendocrine - pathology ; Child ; Female ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Pilot Projects ; Thyroid Neoplasms - chemistry ; Thyroid Neoplasms - pathology</subject><ispartof>Endocrine practice, 2015-06, Vol.21 (6), p.590-594</ispartof><rights>Copyright Allen Press Publishing Services Jun 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-d0f15d1be3891aaba8454ea9cae3fd34d83022a408e625763f05028f9f54ed463</citedby><cites>FETCH-LOGICAL-c406t-d0f15d1be3891aaba8454ea9cae3fd34d83022a408e625763f05028f9f54ed463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1706179580?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25716629$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Milman, Sofiya</creatorcontrib><creatorcontrib>Arnold, Jeffrey L</creatorcontrib><creatorcontrib>Price, Melissa</creatorcontrib><creatorcontrib>Negassa, Abdissa</creatorcontrib><creatorcontrib>Surks, Martin I</creatorcontrib><creatorcontrib>Fleischer, Norman</creatorcontrib><creatorcontrib>Whitney, Kathleen D</creatorcontrib><title>MEDULLARY THYROID CANCER THAT STAINS NEGATIVE FOR CA 19-9 HAS DECREASED METASTATIC POTENTIAL</title><title>Endocrine practice</title><addtitle>Endocr Pract</addtitle><description>Presently, no clinical tools are available to diagnose the metastatic potential of medullary thyroid cancer (MTC) at disease presentation. Surveillance with calcitonin (Ct) and carcinoembryonic antigen (CEA) is currently recommended for the observation and diagnosis of metastatic disease after initial treatment of MTC. Recently, carbohydrate antigen (CA)19-9 staining has been associated with aggressive forms of MTC and metastatic spread. This pilot study explored whether positive CA19-9 staining of MTC tissue is associated with its metastatic potential.
Sixteen cases of MTC were identified, and tissue specimens were immunostained for CA 19-9 and other MTC tumor markers. Clinical information about patients' MTC was collected through a retrospective chart review.
Overall, 63% of the specimens stained positive for CA19-9. The median size of positively staining specimens was 2.6 cm (interquartile range [IQR] 1.2-3.2) compared to 0.7 cm (0.5-1.2) in negatively staining MTC specimens (P = .04). All specimens from patients diagnosed with stage IV MTC stained positive for CA19-9, compared to only 40% of cases that were classified as stages I to III (P = .03). Furthermore, 100% of the primary specimens that were documented to have metastatic spread stained positive for CA19-9. The sensitivity for ruling out stage IV MTC based on negative staining for CA 19-9 was 100%.
Based on these results, we conclude that negative staining of MTC for CA19-9 may be associated with its decreased metastatic potential.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>CA-19-9 Antigen - analysis</subject><subject>Carcinoma, Neuroendocrine - chemistry</subject><subject>Carcinoma, Neuroendocrine - pathology</subject><subject>Child</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pilot Projects</subject><subject>Thyroid Neoplasms - chemistry</subject><subject>Thyroid Neoplasms - pathology</subject><issn>1530-891X</issn><issn>1934-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkV9LwzAUxYMobv558QNIwBcRqkmTtM2LELroCnUdXSYKQsjaVDe2VdtN8NsbcQ716d7L-XE4lwPACUaXFLPoSg4xJSy8zPId0MWcUM-niOy6nRHkRRw_dMBB284Q8hHH0T7o-CzEQeDzLni6k71xmor8Ear-Y54lPRiLQSxzdwoFR0okgxEcyFuhknsJb7Lc6RBzj8O-GMGejHMpRrIH76QSjlZJDIeZkgOViPQI7FVm3trjzTwE4xup4r6XZrdJLFKvoChYeSWqMCvxxBKX1ZiJiSij1vDCWFKVhJYRQb5vKIps4JIHpEIM-VHFK4eVNCCH4Prb93U9WdiysMtVY-b6tZkuTPOhazPVf5Xl9EU_1--aspAwypzB-cagqd_Wtl3pxbQt7HxulrZetxoHnIQYMUYdevYPndXrZune0zhEAQ45i5CjLr6poqnbtrHVNgxG-qs0vSlNZ7mDT3_H36I_LZFPdnCJNg</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Milman, Sofiya</creator><creator>Arnold, Jeffrey L</creator><creator>Price, Melissa</creator><creator>Negassa, Abdissa</creator><creator>Surks, Martin I</creator><creator>Fleischer, Norman</creator><creator>Whitney, Kathleen D</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150601</creationdate><title>MEDULLARY THYROID CANCER THAT STAINS NEGATIVE FOR CA 19-9 HAS DECREASED METASTATIC POTENTIAL</title><author>Milman, Sofiya ; Arnold, Jeffrey L ; Price, Melissa ; Negassa, Abdissa ; Surks, Martin I ; Fleischer, Norman ; Whitney, Kathleen D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-d0f15d1be3891aaba8454ea9cae3fd34d83022a408e625763f05028f9f54ed463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>CA-19-9 Antigen - analysis</topic><topic>Carcinoma, Neuroendocrine - chemistry</topic><topic>Carcinoma, Neuroendocrine - pathology</topic><topic>Child</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pilot Projects</topic><topic>Thyroid Neoplasms - chemistry</topic><topic>Thyroid Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Milman, Sofiya</creatorcontrib><creatorcontrib>Arnold, Jeffrey L</creatorcontrib><creatorcontrib>Price, Melissa</creatorcontrib><creatorcontrib>Negassa, Abdissa</creatorcontrib><creatorcontrib>Surks, Martin I</creatorcontrib><creatorcontrib>Fleischer, Norman</creatorcontrib><creatorcontrib>Whitney, Kathleen D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Endocrine practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Milman, Sofiya</au><au>Arnold, Jeffrey L</au><au>Price, Melissa</au><au>Negassa, Abdissa</au><au>Surks, Martin I</au><au>Fleischer, Norman</au><au>Whitney, Kathleen D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MEDULLARY THYROID CANCER THAT STAINS NEGATIVE FOR CA 19-9 HAS DECREASED METASTATIC POTENTIAL</atitle><jtitle>Endocrine practice</jtitle><addtitle>Endocr Pract</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>21</volume><issue>6</issue><spage>590</spage><epage>594</epage><pages>590-594</pages><issn>1530-891X</issn><eissn>1934-2403</eissn><abstract>Presently, no clinical tools are available to diagnose the metastatic potential of medullary thyroid cancer (MTC) at disease presentation. Surveillance with calcitonin (Ct) and carcinoembryonic antigen (CEA) is currently recommended for the observation and diagnosis of metastatic disease after initial treatment of MTC. Recently, carbohydrate antigen (CA)19-9 staining has been associated with aggressive forms of MTC and metastatic spread. This pilot study explored whether positive CA19-9 staining of MTC tissue is associated with its metastatic potential.
Sixteen cases of MTC were identified, and tissue specimens were immunostained for CA 19-9 and other MTC tumor markers. Clinical information about patients' MTC was collected through a retrospective chart review.
Overall, 63% of the specimens stained positive for CA19-9. The median size of positively staining specimens was 2.6 cm (interquartile range [IQR] 1.2-3.2) compared to 0.7 cm (0.5-1.2) in negatively staining MTC specimens (P = .04). All specimens from patients diagnosed with stage IV MTC stained positive for CA19-9, compared to only 40% of cases that were classified as stages I to III (P = .03). Furthermore, 100% of the primary specimens that were documented to have metastatic spread stained positive for CA19-9. The sensitivity for ruling out stage IV MTC based on negative staining for CA 19-9 was 100%.
Based on these results, we conclude that negative staining of MTC for CA19-9 may be associated with its decreased metastatic potential.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>25716629</pmid><doi>10.4158/EP14357.OR</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1530-891X |
| ispartof | Endocrine practice, 2015-06, Vol.21 (6), p.590-594 |
| issn | 1530-891X 1934-2403 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4573545 |
| source | MEDLINE; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged CA-19-9 Antigen - analysis Carcinoma, Neuroendocrine - chemistry Carcinoma, Neuroendocrine - pathology Child Female Humans Immunohistochemistry Male Middle Aged Pilot Projects Thyroid Neoplasms - chemistry Thyroid Neoplasms - pathology |
| title | MEDULLARY THYROID CANCER THAT STAINS NEGATIVE FOR CA 19-9 HAS DECREASED METASTATIC POTENTIAL |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A11%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MEDULLARY%20THYROID%20CANCER%20THAT%20STAINS%20NEGATIVE%20FOR%20CA%2019-9%20HAS%20DECREASED%20METASTATIC%20POTENTIAL&rft.jtitle=Endocrine%20practice&rft.au=Milman,%20Sofiya&rft.date=2015-06-01&rft.volume=21&rft.issue=6&rft.spage=590&rft.epage=594&rft.pages=590-594&rft.issn=1530-891X&rft.eissn=1934-2403&rft_id=info:doi/10.4158/EP14357.OR&rft_dat=%3Cproquest_pubme%3E3785957011%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1706179580&rft_id=info:pmid/25716629&rfr_iscdi=true |